ProMIS Neurosciences, Inc.
- Market cap
- $113.08M
- 52w range
- $6.27 - $27.40
- Sector
- Healthcare
- Data quality
- 67/100
- fair value estimate
- $6.77
- Margin of safety
- -27.8%
- Moat score
- 5/100
- Return on equity
- -115.7%
- Analyst target
- $32.42
- Target upside
- +245.6%
- Analysts
- 6
About ProMIS Neurosciences, Inc.
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's disease; PMN267 for the treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy. The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for the treatment of Alzheimer's. In addition, it is developing therapies for frontotemporal lobar degeneration, Huntington's disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. is headquartered in Toronto, Canada.
Valuation
Derived from filed metrics · Moderate confidence (67% of the inputs available)
Moat, fair value and rating computed by our valuation engine (ported from the original Python model).